IP Verse

Improved Media For The Expression Of Recombinant Vitamin K-Dependent Proteins

Patent No. EP3383894 (titled "Improved Media For The Expression Of Recombinant Vitamin K-Dependent Proteins") was filed by CSL Behring Lengnau on Dec 2, 2016. The application was issued on May 6, 2020.

Patent Summary

Enhancing the activity of recombinant vitamin K-dependent proteins like factors VII and IX by adding specific compounds to the cell culture media during expression. The compounds are TCA cycle intermediates like alpha-ketoglutaric acid, succinic acid, oxaloacetic acid, malic acid, fumaric acid, and citric acid, as well as the antioxidant glutathione. These compounds provide additional reductive potential to maintain the proper redox environment for vitamin K-dependent protein carboxylation.

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
WALLINGER RICKER SCHLOTTER TOSTMANNFeb 5, 2021KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORF

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3383894

CSL BEHRING LENGNAU
Application Number
EP16806055A
Filing Date
Dec 2, 2016
Status
Granted And Under Opposition
Apr 3, 2020
Publication Date
May 6, 2020
External Links
Slate, Register , Google Patents